


California

Comprehensive **pregnancy and wellness** testing and insights

In California, Quest
Diagnostics® is your
single laboratory testing
source for every phase of
the reproductive journey



Supporting your patients and your practice in California

throughout the pregnancy journey

We've made testing easy with expansive coverage, flexible financial options, easy-to-use online tools, and clinical consultation from our Genomics Services Team.



Supporting California

- 400+ Patient Service Centers for convenient testing
- 2 dedicated laboratories for genetic and molecular testing
- 15 STAT laboratories for quicker turnaround times



Simplified processes

- Quantum® Lab Services Manager makes it easy to order tests and get results when you need them
- MyQuest® online portal and app helps patients securely access results



Accessible testing

- Quest is in-network with the majority of health plans nationwide
- Our Specialty Testing Services team provides prior authorization for certain tests to fulfill health plan coverage requirements
Call 1.855.509.4909
- Easy-to-use financial assistance program helps qualified patients receive testing at no cost or at a reduced patient price
To download an application, please visit
QuestDiagnostics.com/FinancialAssistance



A leader in genetic testing

- Comprehensive test menus for every step in the reproductive journey,
TestDirectory.QuestDiagnostics.com
- Quest has a team of experienced genetic counselors ready to answer your questions
Call 1.866.GENE.INFO (1.866.436.3463)
Monday through Friday from
8:30 AM to 8:00 PM EST





Genetic carrier screening is important for patients considering pregnancy

Maximize clinical insights while minimizing uncertainty

| LABORATORY SCREENING OPTIONS | QUEST TEST | TEST CODE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|-------------------------------|------|-------------------------------|-------------------|------------------|-------|---|------------|-------|----------------|------------|-------|-----------------|-------------|-------|-----------------|-------------|-------|---|------------|-------|-----------------------|---------------|-------|---|--------------|-------|------------------------|--------------|-------|---------------------------------|-------------|-------|-----------------|------------|-------|-----------------------------------|-------------|-------|--------------------|----------------|-------|-------------------------------|---------------|-------|-----------------------|---------------|-------|-------------------|------------|-------|-----------------------------------|--------------|-------|-------------------------|------------|-------|-------------------|-------------|-------|-------------------------|---------------|-------|-------------------------|--------------|-------|-------------------------|-------------|-------|-------|
| Pan-ethnic expanded carrier screen | QHerit® Expanded Carrier Screen^a Reports on 22 inherited disease conditions. The below disease conditions are included in the QHerit panel. If there's an interest in screening for a specific disorder, Quest also offers single-gene screening of these disease conditions. ^{b,c} Please refer to the Gene test code column for ordering information. <table> <tr> <th>Disease conditions</th><th>Gene</th><th>Gene test code^{b,c}</th></tr> <tr><td>Alpha-thalassemia</td><td><i>HBA1/HBA2</i></td><td>11175</td></tr> <tr><td>Beta-hemoglobinopathies (including sickle cell disease)</td><td><i>HBB</i></td><td>14974</td></tr> <tr><td>Bloom syndrome</td><td><i>BLM</i></td><td>90872</td></tr> <tr><td>Canavan disease</td><td><i>ASPA</i></td><td>90905</td></tr> <tr><td>Cystic fibrosis</td><td><i>CFTR</i></td><td>92068</td></tr> <tr><td>Dihydrolipoamide dehydrogenase deficiency</td><td><i>DLD</i></td><td>92046</td></tr> <tr><td>Familial dysautonomia</td><td><i>IKBKAP</i></td><td>90912</td></tr> <tr><td>Familial hyperinsulinism, ABCC8-related</td><td><i>ABCC8</i></td><td>92045</td></tr> <tr><td>Fanconi anemia, type C</td><td><i>FANCC</i></td><td>90897</td></tr> <tr><td>Fragile X syndrome^d</td><td><i>FMR1</i></td><td>16313</td></tr> <tr><td>Gaucher disease</td><td><i>GBA</i></td><td>90907</td></tr> <tr><td>Glycogen storage disease, type 1A</td><td><i>G6PC</i></td><td>90915</td></tr> <tr><td>Joubert syndrome 2</td><td><i>TMEM216</i></td><td>92050</td></tr> <tr><td>Maple syrup urine disease, 1B</td><td><i>BCKDHB</i></td><td>90909</td></tr> <tr><td>Mucopolidosis, type 4</td><td><i>MCOLN1</i></td><td>90899</td></tr> <tr><td>Nemaline myopathy</td><td><i>NEB</i></td><td>92055</td></tr> <tr><td>Niemann-Pick disease, types A & B</td><td><i>SMPD1</i></td><td>90893</td></tr> <tr><td>Spinal muscular atrophy</td><td><i>SMN</i></td><td>39445</td></tr> <tr><td>Tay-Sachs disease</td><td><i>HEXA</i></td><td>90903</td></tr> <tr><td>Usher syndrome, type 1F</td><td><i>PCDH15</i></td><td>92047</td></tr> <tr><td>Usher syndrome, type 3A</td><td><i>CLRN1</i></td><td>92048</td></tr> <tr><td>Walker-Warburg syndrome</td><td><i>FKTN</i></td><td>92051</td></tr> </table> | Disease conditions | Gene | Gene test code ^{b,c} | Alpha-thalassemia | <i>HBA1/HBA2</i> | 11175 | Beta-hemoglobinopathies (including sickle cell disease) | <i>HBB</i> | 14974 | Bloom syndrome | <i>BLM</i> | 90872 | Canavan disease | <i>ASPA</i> | 90905 | Cystic fibrosis | <i>CFTR</i> | 92068 | Dihydrolipoamide dehydrogenase deficiency | <i>DLD</i> | 92046 | Familial dysautonomia | <i>IKBKAP</i> | 90912 | Familial hyperinsulinism, ABCC8-related | <i>ABCC8</i> | 92045 | Fanconi anemia, type C | <i>FANCC</i> | 90897 | Fragile X syndrome ^d | <i>FMR1</i> | 16313 | Gaucher disease | <i>GBA</i> | 90907 | Glycogen storage disease, type 1A | <i>G6PC</i> | 90915 | Joubert syndrome 2 | <i>TMEM216</i> | 92050 | Maple syrup urine disease, 1B | <i>BCKDHB</i> | 90909 | Mucopolidosis, type 4 | <i>MCOLN1</i> | 90899 | Nemaline myopathy | <i>NEB</i> | 92055 | Niemann-Pick disease, types A & B | <i>SMPD1</i> | 90893 | Spinal muscular atrophy | <i>SMN</i> | 39445 | Tay-Sachs disease | <i>HEXA</i> | 90903 | Usher syndrome, type 1F | <i>PCDH15</i> | 92047 | Usher syndrome, type 3A | <i>CLRN1</i> | 92048 | Walker-Warburg syndrome | <i>FKTN</i> | 92051 | 94372 |
| Disease conditions | Gene | Gene test code ^{b,c} | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Alpha-thalassemia | <i>HBA1/HBA2</i> | 11175 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Beta-hemoglobinopathies (including sickle cell disease) | <i>HBB</i> | 14974 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Bloom syndrome | <i>BLM</i> | 90872 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Canavan disease | <i>ASPA</i> | 90905 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cystic fibrosis | <i>CFTR</i> | 92068 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dihydrolipoamide dehydrogenase deficiency | <i>DLD</i> | 92046 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Familial dysautonomia | <i>IKBKAP</i> | 90912 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Familial hyperinsulinism, ABCC8-related | <i>ABCC8</i> | 92045 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Fanconi anemia, type C | <i>FANCC</i> | 90897 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Fragile X syndrome ^d | <i>FMR1</i> | 16313 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gaucher disease | <i>GBA</i> | 90907 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Glycogen storage disease, type 1A | <i>G6PC</i> | 90915 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Joubert syndrome 2 | <i>TMEM216</i> | 92050 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Maple syrup urine disease, 1B | <i>BCKDHB</i> | 90909 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mucopolidosis, type 4 | <i>MCOLN1</i> | 90899 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Nemaline myopathy | <i>NEB</i> | 92055 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Niemann-Pick disease, types A & B | <i>SMPD1</i> | 90893 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Spinal muscular atrophy | <i>SMN</i> | 39445 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Tay-Sachs disease | <i>HEXA</i> | 90903 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Usher syndrome, type 1F | <i>PCDH15</i> | 92047 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Usher syndrome, type 3A | <i>CLRN1</i> | 92048 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Walker-Warburg syndrome | <i>FKTN</i> | 92051 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prenatal carrier | Prenatal Carrier Panel^a Includes CFvantage® (cystic fibrosis), spinal muscular atrophy (SMA), Fragile X syndrome ^d | 93349 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cystic fibrosis | CFvantage Cystic Fibrosis Expanded Screen 161 CF variants, including the 23 common variants aligned with ACOG guidelines | 92068 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Fragile X | XSense®, Fragile X ^d with Reflex ^f | 16313 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Spinal muscular atrophy | SMA Carrier Screen | 39445 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Please contact our genetic counselors with any questions concerning your patient's genetic tests.

Call 1.866.GENE.INFO (1.866.436.3463) Monday through Friday 8:30 AM to 8:00 PM EST

^a QHerit is a carrier "screening" test, and it screens for variations in genes linked to certain health disorders, which can be passed from parents to children. For a full list of all 22 genes that QHerit screens, visit QHerit.com. If QHerit results suggest that a patient may be a carrier of a gene variation that can cause a health disorder in her offspring, it is recommended that her reproductive partner be offered genetic screening, and that genetic counseling be provided. Pregnancy management decisions should not be based on the results of QHerit alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic variation, and may be lower for rare conditions. QHerit is a laboratory developed test that has been developed and validated, pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA), and as such it has not been reviewed by FDA.

^b While we offer comprehensive testing, some patients may have an interest in screening for a specific disorder, such as cystic fibrosis. For these patients, Quest Diagnostics offers single-gene screening. Consultation available on genetic test selection and results interpretation: 1.866.GENE.INFO (1.866.436.3463).

^c Please note that Quest offers a variety of single gene and gene panel testing. For the genetic panel noted in this document, there may be single gene tests or smaller panels that may be applicable for your patient. Panel and Profile components may be ordered separately. Refer to the Quest Diagnostics Test Directory for further information: <https://testdirectory.questdiagnostics.com/test/home>.

^d Designated X-linked diseases.

^e Individual testing is available for partners of known carriers, and individual panel components can be ordered separately.

^f Reflex testing may be performed at an additional charge.



Screening is an important part of a healthy pregnancy

Appropriate prenatal testing is a crucial part of caring for people who are expecting

1st trimester

| LABORATORY SCREENING OPTIONS | QUEST TEST | TEST CODE |
|---|--|-----------------------|
| OB panel (can be ordered as a panel or individually)[§] | Obstetric Panel | 20210 |
| OB panel, individual components | Complete blood count (CBC) (includes Differential and Platelets) | 6399 |
| | Antibody Screen, red blood cells (RBC) with Reflex to Identification, Titer, and Antigen Typing ^f | 795 |
| | ABO Group and Rh Type | 7788 |
| | Rapid plasma reagin (RPR) (Diagnosis) with Reflex to Titer and Confirmatory Testing ^f (non-treponemal screening for syphilis) | 36126 |
| | Hepatitis B Surface Antigen with Reflex Confirmation ^f | 498 |
| | Rubella Antibody (IgG), Immune Status | 802 |
| Additional OB Panel | Obstetric Panel with Fourth Generation HIV Individual components [§] | 93802 |
| Additional OB Panel component | HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes ^f | 91431 |
| Additional OB Panel | Obstetric Panel with Fourth Generation HIV, Hepatitis C Antibody with Reflex | 12075 |
| Additional OB Panel component | Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR | 8472 |
| Additional 1st trimester tests | | |
| Cervical cytology screening, if indicated ^h | Image-Guided Pap with Age-Based Screening Protocols ^h | 91384 |
| | Image-Guided Pap with Age-Based Screening with CT/NG ^h | 91385 |
| | Image-Guided Pap with Age-Based Screening with CT/NG, <i>Trichomonas</i> ^h | 91386 |
| | Pap alone | See note ^h |

^f Reflex testing may be performed at an additional charge.

[§] If Antibody Screen is positive, Antibody Identification, Titer, and Antigen Typing will be performed at an additional charge. If RPR screen is reactive, RPR Titer and FTA Confirmatory testing will be performed at an additional charge. When only 1 test, Hepatitis B Surface Antigen, is ordered to diagnose Hepatitis B in a pregnant person, additional tests such as liver enzymes should be ordered to confirm the diagnosis.

^h The age-based offerings are based on ACOG recommendations and include image-guided Pap tests. Non-imaged Paps as well as conventional Paps are also available at Quest Diagnostics. Individual panel components can be ordered separately.



| LABORATORY SCREENING OPTIONS | QUEST TEST | TEST CODE |
|---|---|-------------------------------------|
| Additional 1st trimester tests | | |
| Urinalysis/Urine culture | Urinalysis, Complete | 5463 |
| | Urinalysis, Complete, with Reflex to Culture ^f | 3020 |
| | Culture, Urine, Routine | 395 |
| | Urinalysis with Reflex to Microscopic ^f | 7909 |
| Zika testing | Zika Virus RNA, Qualitative, Real-Time RT-PCR | 93870 |
| | Zika Virus RNA, Qualitative, Real-Time RT-PCR Panel, Serum/Urine | 94221 |
| Although rates of Zika virus infection have decreased in the United States, obstetricians/gynecologists and other healthcare providers should continue to assess their patients for potential exposure based on travel or sexual history and test symptomatic patients with possible exposure and pregnant people with ongoing exposure regardless of symptoms in accordance with the CDC recommendations. ¹ | | |
| Fetal aneuploidy 1st trimester testing | | |
| First Trimester Screen | First Trimester Screen, hCG The screen includes pregnancy-associated plasma protein-A (PAPP-A), human chorionic gonadotropin (hCG), nuchal translucency (NT) test; and risk assessments for trisomy 21 and trisomy 18 | 16145 |
| Maternal Serum Screen (Part 1) | Stepwise, Part 1 The screen includes PAPP-A, hCG, NT test; and risk assessments for trisomy 21 and trisomy 18 | 16463 |
| | Serum Integrated Screen, Part 1 This screen includes PAPP-A; and risk assessments for trisomy 21 and trisomy 18 reported after Part 2 | 16165 |
| | Sequential Integrated Screen, Part 1 This screen includes PAPP-A, hCG, NT test; and risk assessments for trisomy 21 and trisomy 18 | 16131 |
| | Integrated Screen, Part 1 This screen includes PAPP-A, NT test; and risk assessments for trisomy 21 and trisomy 18 reported after Part 2 | 16148 |
| Noninvasive prenatal screening | GDSP cfDNA Panel ⁱ | Available through CalGenetic Portal |
| Sex chromosome aneuploidies (SCAs) and microdeletions | CA SCA and Microdeletions ⁱ | 12296 |
| Sex chromosome aneuploidies (SCAs) only | CA SCA ⁱ | 12299 |
| Diagnostic Chromosomal Analysis via chorionic villus sampling (CVS), if indicated | Chromosome Analysis, Chorionic Villus Sample (CVS) | 14592 |

^f Reflex testing may be performed at an additional charge.

ⁱ The GDSP (Genetic Disease Screening Program) cfDNA Panel is a cell-free DNA test that can screen for increased risk of trisomy 21, trisomy 18 and trisomy 13, which are fetal chromosomal abnormalities that may cause birth defects. It can also screen for fetal sex, if elected. Supplemental cfDNA screening is also available for sex chromosome aneuploidies (SCAs) and/or microdeletions. The GDSP cfDNA Panel, as well as the supplemental tests for SCA and/or microdeletions, are "screening" tests, not a diagnostic tests, and therefore all positive (ie, increased risk) results should be followed by genetic counseling and further diagnostic testing and procedures, when clinically indicated. Pregnancy management decisions should not be based on the results of a cfDNA test alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic marker, and may be lower for rare conditions. Performance data for the GDSP cfDNA Panel and for the supplemental screening tests may be obtained by contacting Quest Diagnostics at 1.866.GENE.INFO (1.866.436.3463).

Individual panel components can be ordered separately.



| LABORATORY SCREENING OPTIONS | QUEST TEST | TEST CODE |
|---|---|--------------|
| Infectious disease 1st trimester tests | | |
| Tuberculosis (TB), if indicated ⁱ | QuantiFERON®-TB Gold Plus, 1 Tube | 36970 |
| | QuantiFERON-TB Gold Plus, 4 Tubes, Draw Site Incubated | 36971 |
| | T-SPOT®.TB | 37737 |
| Chlamydia ^j | <i>Chlamydia trachomatis</i> RNA, TMA, Urogenital | 11361 |
| Gonorrhea, if indicated ^k | <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital | 11362 |
| Chlamydia and gonorrhea | <i>Chlamydia trachomatis</i> / <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital | 11363 |
| HIV testing | HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes ^f | 91431 |
| Hepatitis C testing | Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR ^f | 8472 |
| | Hepatitis C Antibody with Reflex to HCV RNA, PCR w/Reflex to Genotype, LIPA ^f | 94345 |
| Syphilis | Syphilis Antibody Cascading Reflex | 90349 |

^f Reflex testing may be performed at an additional charge.

^j Risk factors include known HIV infection; close contact with individuals known or suspected to have TB; medical risk factors such as diabetes, lupus, cancer, alcoholism, and drug addiction; birth in or emigration from countries with high prevalence; being medically underserved; homelessness; living or working in long-term care facilities, such as correctional institutions, mental health institutions, and nursing homes.

^k If positive, test-of-cure should be performed within 3–4 weeks post-treatment.

CDC recommends STI screening during pregnancy

According to The Centers for Disease Control and Prevention (CDC), pregnant patients should be tested for some STIs, starting early in their pregnancy and repeating close to delivery, as needed.

They also recommend open, honest conversations with pregnant patients and, when possible, their sex partners about symptoms and any high-risk sexual behaviors.²





Maintaining prenatal care is essential, even as the due date approaches

Second and third trimester screening can provide important insights to help you and your patient make informed decisions

2nd trimester

| LABORATORY SCREENING OPTIONS | QUEST TEST | TEST CODE |
|---|---|-------------------------------------|
| CBC | CBC (includes Differential and Platelets) This screen includes white blood count (WBC), RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (absolute and percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils) | 6399 |
| | CBC (H/H, RBC, Indices, WBC, Plt) This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count | 1759 |
| | Hematocrit | 509 |
| | Hemoglobin | 510 |
| Gestational diabetes screening | Glucose, Gestational Screen (50g), 135 Cutoff (ACOG supported 1st step of 2-step gestational diabetes mellitus (GDM) evaluation) | 8477 |
| | Glucose, Gestational Screen (50g), 140 Cutoff (ACOG supported 1st step of 2-step GDM evaluation) | 19833 |
| | Glucose Tolerance Test, Gestational, 4 Specimens (100g) (ACOG supported 2nd step of 2-step GDM valuation) | 6745 |
| Additional 2nd trimester testing | | |
| Quad Screen | Quad Screen This screen includes alpha-fetoprotein (AFP), unconjugated estriol (uE3), hCG, and inhibin A (DIA); and risk assessments for trisomy 21, trisomy 18, and open neural tube defects (ONTD) | 30294 |
| Maternal Serum Screen (Part 2) | Serum Integrated Screen, Part 2 This screen includes AFP, uE3, hCG, DIA, and PAPP-A from Serum Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD | 16167 |
| | Stepwise, Part 2 This screen includes AFP, uE3, hCG, DIA, and PAPP-A, hCG, NT from Stepwise, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD | 16465 |
| | Sequential Integrated Screen, Part 2 This screen includes AFP, uE3, hCG, DIA, and PAPP-A, hCG, NT from Sequential Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD | 16133 |
| | Integrated Screen, Part 2 This screen includes AFP, uE3, hCG, DIA, and PAPP-A, NT from Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD | 16150 |
| Maternal Serum Alpha-Fetoprotein | Maternal Serum AFP This screen includes AFP and risk assessment for ONTD | Available through CalGenetic Portal |
| Diagnostic Chromosomal Analysis via amniocentesis, if indicated | Chromosome Analysis, Amniotic Fluid | 14590 |



3rd trimester

| LABORATORY SCREENING OPTIONS | QUEST TEST | TEST CODE |
|---|---|-----------|
| CBC | CBC (includes Differential and Platelets) This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (absolute and percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils) | 6399 |
| | CBC (H/H, RBC, Indices, WBC, Plt) This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count | 1759 |
| | Hematocrit | 509 |
| | Hemoglobin | 510 |
| D (Rh) antibody screen | Antibody Screen, RBC with Reflex to Identification, Titer, and Antigen Typing ^f | 795 |
| Group B streptococcal disease | <i>Streptococcus</i> Group B Culture | 5617 |
| | <i>Streptococcus</i> Group B with Susceptibility Culture | 15090 |
| | <i>Streptococcus</i> Group B DNA, PCR with Broth Enrichment | 91768 |
| | <i>Streptococcus</i> Group B DNA, PCR with Broth Enrichment and Reflex to Susceptibility ^f | 91770 |
| Chlamydia (if patient tested positive or is high risk due to age or lifestyle) | <i>Chlamydia trachomatis</i> RNA, TMA, Urogenital | 11361 |
| Gonorrhea (if patient tested positive or is high risk due to age or lifestyle) | <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital | 11362 |
| Chlamydia and gonorrhea (if patient tested positive or is high risk due to age or lifestyle) | <i>Chlamydia trachomatis/Neisseria gonorrhoeae</i> RNA, TMA, Urogenital | 11363 |
| RPR (if patient tested positive or is high risk due to age or lifestyle) | RPR (Diagnosis) with Reflex to Titer and Confirmatory Testing ^f | 36126 |
| HIV testing (if patient is high risk due to lifestyle) | HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes ^f | 91431 |

^f Reflex testing may be performed at an additional charge.

Individual panel components can be ordered separately.



For more information, contact your Quest Diagnostics sales representative or call **1.866.MYQUEST (1.866.697.8378)**

References

1. CDC. New Zika and dengue testing guidance (Updated November 2019). Updated December 2, 2019. Accessed September 14, 2022. <https://www.cdc.gov/zika/hc-providers/testing-guidance.html>
2. CDC. STDs during pregnancy - CDC detailed fact sheet. Updated April 12, 2022. Accessed August 16, 2022. <https://www.cdc.gov/std/pregnancy/stdfact-pregnancy-detailed.htm>

As with any test, the tests listed above may yield false positives or negatives, and the positive predictive value of a test may be lower for rare conditions. Please contact our genetic counselors with any questions concerning your patient's genetic tests. Call 1.866.GENE.INFO (1.866.436.3463) Monday through Friday 5:30 AM to 5:00 PM PST.

Test codes may vary by location. Please contact your local laboratory for more information.

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. SB9950-CA 2/2023